ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2014, Vol. 23 ›› Issue (1): 53-57.

• 论文 • 上一篇    下一篇

可溶性尿激酶型纤溶酶原激活物受体与局灶节段性肾小球硬化

  

  • 出版日期:2014-02-28 发布日期:2014-02-25

Soluble urokinase-type plasminogen activator receptor and focal segmental glomerulosclerosis

  • Online:2014-02-28 Published:2014-02-25

摘要:

摘要:局灶节段性肾小球硬化(FSGS)是引起终末期肾脏疾病的主要原因,足细胞损伤是FSGS发生发展的中心环节。循环因子一直被认为是FSGS的致病因素。近来发现,循环中可溶性尿激酶型纤溶酶原激活物受体(suPAR)通过激活足细胞β3整合素引起损伤、脱落,导致FSGS发生,并且发现2/3的FSGS患者血循环中suPAR升高,从而引起广泛关注。本文我们将对suPAR与FSGS发病的关系、suPAR在FSGS患者中的特异性,以及suPAR在FSGS疗效观察中的作用等方面进行系统总结。

关键词: 局灶节段性肾小球硬化,  , 足细胞,  , 可溶性尿激酶型纤溶酶原激活物受体

Abstract:

ABSTRACT   Focal segmental glomerulosclerosis (FSGS) is a major cause of end-stage renal disease (ESRD). And podocyte plays a key role in the development of  FSGS. Circulating permeability factor has been considered to be pathogenic for FSGS. Recently,  it had found that, by binding to β3 integrin on podocytes, suPAR (soluble urokinase-type plasminogen activator receptor) induced podocyte foot process effacement, proteinuria and initiation of FSGS. Furthermore, high concentration of serum suPAR had been confirmed in approximately two-thirds of patients with FSGS. Here, we will review the role and specificity of suPAR in primary FSGS, and the role of suPAR in clinical practice of FSGS.

Key words: Focal segmental glomerulosclerosis,   , podocyte ,   , soluble urokinase-type plasminogen activator receptor